ClouDr Group (HKSE:09955) Cash, Cash Equivalents, Marketable Securities : HK$651 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is ClouDr Group Cash, Cash Equivalents, Marketable Securities?

ClouDr Group's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (HK$807.58 Mil) to Jun. 2023 (HK$732.17 Mil) but then stayed the same from Jun. 2023 (HK$732.17 Mil) to Dec. 2023 (HK$650.90 Mil).

ClouDr Group's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (HK$1,369.66 Mil) to Dec. 2022 (HK$807.58 Mil) and declined from Dec. 2022 (HK$807.58 Mil) to Dec. 2023 (HK$650.90 Mil).

ClouDr Group Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for ClouDr Group's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClouDr Group Cash, Cash Equivalents, Marketable Securities Chart

ClouDr Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

668.95

1,083.75

1,369.66

807.58

650.90

ClouDr Group Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			1,369.66	679.12	807.58	732.17	650.90

ClouDr Group Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

ClouDr Group (HKSE:09955) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

ClouDr Group Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of ClouDr Group's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

ClouDr Group (HKSE:09955) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » ClouDr Group Ltd (HKSE:09955) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

H3L:Germany

Address

No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.cloudr.cn

ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.

Executives

Trident Trust Company (hk) Limited	2301 Trustee
Data Vantage Development Limited	2201 Interest of corporation controlled by you
Kuang Ming	2201 Interest of corporation controlled by you
Prime Forest Assets Limited	2101 Beneficial owner
Shang Hai Qi Ji Ke Ji He Huo Qi Ye You Xian He Huo
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Zhao Yin Guo Ji Jin Rong You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Ho Chi Sing	2201 Interest of corporation controlled by you
China Merchants Bank Co., Ltd.
Zhou Quan	2201 Interest of corporation controlled by you
Idg China Venture Capital Fund Gp Iv Associates Ltd.	2201 Interest of corporation controlled by you
Haoyuan Health Limited	2101 Beneficial owner
Yass Jeffrey Steven

ClouDr Group (HKSE:09955) Headlines

No Headlines